"Clinical trial lead, Dr. Gary Siskin, has advised the Ministry of Health that he was unable to meet the target enrolment necessary for the study to produce statistically valid results. Despite Saskatchewan’s 86 planned participants, the research team could not recruit enough total participants to meet United States government requirements for a clinical trial."
UPDATE on Cancelled Trial from CTV News--
"Siskin told CTV News that he’s “very disappointed” the trial had to be cancelled.
He spoke about the difficulty in getting people to enrol in the study, as participants seemed reluctant because of the 50/50 chance that they would receive a placebo treatment instead of the real thing.
Siskin, an interventional radiologist, has treated several hundred patients outside of the trial -- but he stopped in favour of doing formal research into the treatment. His was the only FDA-approved study for CCSVI therapy.
He says despite the setback, his interest in CCSVI is undeterred. "This in no way diminishes my interest in CCSVI," he said.
He told CTV News that in his opinion, narrowed veins in patients with symptoms of MS "is a diagnostic entity” and is “real.”
"I've seen too many people who have responded to treatment to say they are making it up," Siskin said.
Saskatchewan Health Minister Dustin Duncan also expressed disappointment at the news for the approximately 3,500 MS sufferers in his province.
“Our government wants to do everything it can to search for answers and further the science for people with MS,” said Duncan. “That’s why Saskatchewan was supportive of this trial and will continue to be supportive of research that may provide answers for those with MS and their families.”
http://www.ctvnews.ca/health/clinical-t ... -1.1446888
The Saskatchewan government had committed $2.2 million to have 86 patients from the province take part in the trial. However, it was difficult to find people with MS who met the study criteria and were willing to be part of a placebo controlled trial. Many patients want to know that they are being treated, rather than risk an invasive venoplasty procedure without treatment. Participants in this trial would not know whether or not they had been treated for CCSVI, and this may have made patients resistant to enrolling for participation. Funding for and patient interest in the American patient arm of the trial was also an issue. Because of these factors, the Albany Medical Center team decided to stop the trial.
Users browsing this forum: MSandI